People: Entera Bio Ltd (ENTX.OQ)

ENTX.OQ on NASDAQ Stock Exchange Capital Market

15 Nov 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Schwartz, Phillip 

Dr. Phillip Schwartz, Ph.D., is Executive Vice President, President - Research & Development of the Company. He has more than ten years of biotech and pharmaceutical industry experience. He has held multiple positions in medical affairs, business development and clinical trial development at Serono and Endo Pharmaceuticals. He has also consulted privately and as an associate of Health Advances, LLC, for more than 20 large biotech and pharmaceutical companies. His former position was as the Manager of Clinical Affairs at Endo Pharmaceuticals. He has also worked as consultant for a number of venture capital firms.Dr. Schwartz completed his BA in psychology and architecture at Columbia University. He then studied and worked in neurobiology with Nobel Laureate Prof. Torsten Wiesel of the Rockefeller University, for more than two years. After completing his project, Dr. Schwartz studied immunology with Prof. Irun Cohen at the Weizmann Institute, receiving his MSc, in 1991. In 1997 Dr. Schwartz received his PhD in neurobiology/ development/ oncology from Harvard Medical School. In addition to his scientific training, Dr. Schwartz completed two years of clinical studies as part of his program at Harvard Medical School. After completing his PhD, Dr. Schwartz was a fellow in pediatric oncology at the Dana Farber Cancer Institute and an officer of Harvard University/ Medical School. Dr. Schwartz has multiple publications in tier one peer reviewed journals and has presented papers at numerous international conferences.

Basic Compensation

Total Annual Compensation, USD 450,797
Restricted Stock Award, USD 120,289
Long-Term Incentive Plans, USD --
All Other, USD 44,497
Fiscal Year Total, USD 615,583

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --